-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The most profitable business in the first half of 2022 is
On the evening of August 29, Jiuan Medical disclosed a quite eye-catching financial report for the first half of 2022, in the first half of this year, the company achieved revenue of 23.
In the first half of this year, the company achieved revenue of 23.
■ iHealth kit sales revenue increased overseas
Jiuan Medical has made a lot of money, among which the sales of iHealth new crown antigen detection reagent in the United States are the most important source of
Source: Jiuan Medical Financial Report
Specifically, in the "operating income composition" of Jiuan Medical's semi-annual report, the sales amount of iHealth new crown antigen series products was 23.
Source: Jiuan Medical Financial Report
It is worth noting that as of now, among the 377 companies that have disclosed semi-annual reports in the A-share pharmaceutical and biological sector, the net profit growth rate of Jiuan Medical ranks first
■ Bid for a large order from the US government, with an exclusive share of 70%.
■ Bid for a large order from the US government, with an exclusive share of 70%.
According to the survey information, in the first batch of 500 million people in the US government's public bidding order for the new crown antigen self-testing agent box, Jiuan Medical got about 70% of the share
In 2022, the U.
■ 16 times the "big bull" once again hit the limit!
■ 16 times the "big bull" once again hit the limit!Speaking of Jiuan Medical, the first impression of shareholders is the "king of demons", as the absolute demon king at the end of 2021, the stock price has soared 10 times in just 2 months from November 1, 2021 to January 1, 2022!
In the early trading of August 30, the stock price of Jiuan Medical, which had soared 16 times in half a year, opened high and went high, and once hit the limit
■ The new crown vaccine track has diverged, and the net profit of the 30 billion vaccine giant has fallen by 98%
■ The new crown vaccine track has diverged, and the net profit of the 30 billion vaccine giant has fallen by 98%On the evening of August 26, 688185 disclosed its interim results
Source: CanSino earnings report
Judging from the situation disclosed in the semi-annual report, it is now affected by the changes in the new crown vaccine market, and the performance of CanSino Biologics on the basis of last year's high profitability has fallen
In response to the decline in performance, the company said that the decrease in revenue was mainly due to lower demand for vaccines due to changes in vaccine product prices and slower growth in global COVID-19 vaccination rates
